Latest Breaking News On - Josephine belluardo - Page 8 : comparemela.com

Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference

Compugen to Present at the Oppenheimer 31st Annual Healthcare Conference USA - English Share this article Share this article HOLON, Israel, March 8, 2021 /PRNewswire/ Compugen Ltd. (NASDAQ: CGEN), a leader in predictive discovery and development of first-in-class therapeutics for cancer immunotherapy, today announced that management will present at the Oppenheimer 31 st Annual Healthcare Conference (virtual), on Tuesday, March 16, 2021 at 10:40 AM ET. A live webcast of the presentation will be available on Compugen s website. A replay will be available after the presentation ends. About Compugen Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable, predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Compugen s lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a P

Nanotechnology Now - Press Release: Arrowhead Pharmaceuticals Files IND to Begin Phase 2b Study of ARO-APOC3 in Patients with Severe Hypertriglyceridemia

Compugen Reports Fourth Quarter and Full Year 2020 Results

Compugen Reports Fourth Quarter and Full Year 2020 Results USA - English Encouraging signals of anti-tumor activity demonstrated across COM701 Phase 1 combination and monotherapy studies with durable responses, including a complete response, in tumor types typically unresponsive to checkpoint inhibitors Expansion of DNAM axis clinical programs to include Phase 1b cohort expansion of COM701 with Opdivo® in Q2 2021 and Phase 1 COM701 with COM902 dual combination study in 2H 2021 Initial data from ongoing dose escalation studies of triple combination of COM701 with Bristol Myers Squibb s Opdivo® and TIGIT Inhibitor, and COM902 monotherapy, both on track for Q4 2021 News provided by Share this article

Compugen Reports Fourth Quarter and Full Year 2020 Results

Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)

Published: Feb 03, 2021  - First potentially disease-modifying gene therapy for GM2 gangliosidosis to enter clinical studies - Expect to continue patient identification, screening, and enrollment in Stage 1 of the study throughout 2021 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 03, 2021 (GLOBE NEWSWIRE) Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that the first patient with infantile Tay-Sachs disease has been dosed in a Phase 1/2 trial evaluating AXO-AAV-GM2, an investigational gene therapy for the treatment of GM2 gangliosidosis, also known as Tay-Sachs or Sandhoff disease.